Rusheen Aaron E, Smadbeck James B, Schimmenti Lisa A, Klee Eric W, Link Michael J, Vasmatzis George, Carlson Matthew L
Medical Scientist Training Program, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States.
Biomarker Discovery Program, Center of Individualized Medicine, Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States.
J Neurol Surg B Skull Base. 2019 Feb;80(1):10-17. doi: 10.1055/s-0038-1655759. Epub 2018 May 31.
Cahan's criteria have been utilized since 1948 to establish causality between prior radiation treatment and the development of secondary malignancy. One major criterion specifies that histological and radiographic evidence collected before and after radiation treatment must confirm separate tumor types; however, pretreatment biopsy is rarely obtained prior to radiosurgery for vestibular schwannoma and many other skull base and cranial lesions. Therefore, in these cases Cahan's criteria cannot be validly applied. This article proposes an update to Cahan's criteria using modern molecular genetic analysis for cases lacking baseline histopathology. Mate-pair sequencing and whole exome sequencing of a cerebellopontine angle undifferentiated high-grade pleomorphic sarcoma (UHGPS) that developed after stereotactic radiosurgery of a presumed benign vestibular schwannoma. Mate-pair sequencing and whole exome sequencing of the sarcoma revealed complex chromosomal aberrations. Notably, the tumor contained a deletion in the gene at 22q12 and an in-frame deletion on exon 5 of the remaining copy of . Biallelic events impacting are atypical for UHGPS but are characteristic for vestibular schwannoma. These findings help support the conclusion that the UHGPS arose from a benign vestibular schwannoma all along. Next-generation sequencing can be successfully applied to a radiation-induced sarcoma when both the original and malignant tumors harbor separate signature genetic markers. As our understanding of the genetic profile of various tumors expand, we believe that next-generation sequencing and other genomic tools will play an increasingly important role in establishing causality between radiation and the development of secondary malignancy.
自1948年以来,卡汉标准一直被用于确定既往放射治疗与继发性恶性肿瘤发生之间的因果关系。一个主要标准规定,放射治疗前后收集的组织学和影像学证据必须证实为不同的肿瘤类型;然而,对于前庭神经鞘瘤以及许多其他颅底和颅脑病变,在进行放射外科手术之前很少进行治疗前活检。因此,在这些情况下,卡汉标准无法有效应用。 本文针对缺乏基线组织病理学的病例,提出使用现代分子遗传学分析对卡汉标准进行更新。 对一例推测为良性前庭神经鞘瘤立体定向放射外科手术后发生的桥小脑角未分化高级别多形性肉瘤(UHGPS)进行配对末端测序和全外显子组测序。 对该肉瘤进行配对末端测序和全外显子组测序发现了复杂的染色体畸变。值得注意的是,肿瘤在22q12处的基因存在缺失,并且在该基因剩余拷贝的外显子5上存在框内缺失。影响该基因的双等位基因事件在UHGPS中并不典型,但却是前庭神经鞘瘤的特征。这些发现有助于支持该UHGPS一直起源于良性前庭神经鞘瘤的结论。 当原始肿瘤和恶性肿瘤都具有各自独特的标志性遗传标记时,下一代测序可以成功应用于放射诱发的肉瘤。随着我们对各种肿瘤基因谱的了解不断扩展,我们相信下一代测序和其他基因组工具在确定放射与继发性恶性肿瘤发生之间的因果关系中将发挥越来越重要的作用。